Category : IBD

Marion Leclerc is a French microbiologist working at INRA  (the French National Institute for Agricultural Research) Jouy-en-Josas Centre. She spoke with Gut Microbiota for Health about her various areas of research.   What research are you doing on functional characterization of the gut microbiota? I am now [cooperating] with Patricia Lepage... we have different projects where we try to go from known…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Marion Leclerc is a French microbiologist working at INRA  (the French National Institute for Agricultural Research) Jouy-en-Josas Centre. She spoke with Gut Microbiota for Health about her various areas of research.   What research are you doing on functional characterization of the gut microbiota? I am now [cooperating] with Patricia Lepage... we have different projects where we try to go from known…

Kristina Campbell
Science writer Kristina Campbell (M.Sc.), from British Columbia (Canada), specializes in communicating about the gut microbiota, digestive health, and nutrition. Author of the best selling Well-Fed Microbiome Cookbook, her freelance work has appeared in publications around the world. Kristina joined the Gut Microbiota for Health publishing team in 2014.  Find her on: GoogleTwitter

Discover the first video interview from our Gut Microbiota for Health World Summit 2014 serie. The event took place in Miami, Florida, USA on March 8-9, 2014. Prof. Balfour Sartor hosted a workshop on the role of intestinal microbiota in IBD and shared his conclusions with us.     https://www.gutmicrobiotaforhealth.com/videos/gmfh2014-interviews/Balfour-Sartor.mp4

GMFH Editing Team
GMFH Editing Team

Discover the first video interview from our Gut Microbiota for Health World Summit 2014 serie. The event took place in Miami, Florida, USA on March 8-9, 2014. Prof. Balfour Sartor hosted a workshop on the role of intestinal microbiota in IBD and shared his conclusions with us.     https://www.gutmicrobiotaforhealth.com/videos/gmfh2014-interviews/Balfour-Sartor.mp4

GMFH Editing Team
GMFH Editing Team

Catherine Juste studied agronomic engineering, and then became Doctor of Science, specializing in nutrition and physiology. She became passionate about environmental microbiology and is currently developing environmental proteomics of the gut microbes at INRA. She developed an innovative preparative pipeline to explore myriads of bacterial proteins that are expressed in the lumen gut of human hosts, and that may have…

GMFH Editing Team
GMFH Editing Team

Catherine Juste studied agronomic engineering, and then became Doctor of Science, specializing in nutrition and physiology. She became passionate about environmental microbiology and is currently developing environmental proteomics of the gut microbes at INRA. She developed an innovative preparative pipeline to explore myriads of bacterial proteins that are expressed in the lumen gut of human hosts, and that may have…

GMFH Editing Team
GMFH Editing Team

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

Machiels et al. recently described that the composition of the faecal microbiota of patients suffering from ulcerative colitis differs from that of healthy individuals: they found a reduction in two well-known butyrate-producing bacteria of the Firmicutes phylum, Roseburia hominis and Faecalibacterium prausnitzii. This has been confirmed in other studies. The dysbiosis found in the two inflammatory bowel diseases (IBD) i.e. Crohn’s…

Philippe Marteau
Gastroenterologist, Head of the Medico-surgical department of Hepato-gastroenterology, Lariboisière Hospital, Paris. Professor of gastroenterology at Paris 7 University. Philippe Marteau received his PhD from the University Paris XI, France, in 1994. His main research interest is Physiopathology of the human intestinal ecosystem (intestinal microbiota in health and disease): role of the ecosystem in the development of intestinal diseases, especially inflammatory bowel diseases (Crohn’s disease, ulcerative colitis...) and irritable bowel syndrome (IBS); treatment or prevention (1st axis: description of the ecosystem in different physiological situations and pathological conditions -inflammatory bowel disease, cancers, polyps- / 2nd axis: modulation of the ecosystem using probiotics, prebiotics or other food substrates). Philippe Marteau has published >270 publications in peer reviewed scientific journals. He is member of the French Society of Gastroenterology, ECCO and of IOIBD (International Organization of Inflammatory Bowel Diseases), GETAID. He is president of the French “Collégiale des Universitaires d’Hépatogastroentérologie”. He has been principal investigator of several randomized controlled trials using drugs or probiotics in the treatment of various gastrointestinal diseases, especially inflammatory bowel disease and irritable bowel syndrome.

One year at a glance is the compilation of the most relevant and popular content on gut microbiota as published on the GMFH website.   The topic is rapidly growing across all fields of expertise and questions it raises are endless. It seems that hardly a day goes without gut microbiota being related to the health status (enterotypes, second genotype, ageing),…

GMFH Editing Team
GMFH Editing Team

One year at a glance is the compilation of the most relevant and popular content on gut microbiota as published on the GMFH website.   The topic is rapidly growing across all fields of expertise and questions it raises are endless. It seems that hardly a day goes without gut microbiota being related to the health status (enterotypes, second genotype, ageing),…

GMFH Editing Team
GMFH Editing Team

We have composed short summaries of the workshops that were organized during the Gut Microbiota for Health Summit (Madrid, February 2013).   Here is the list of workshops: “Gut Microbiota and functional bowel disorders” “Gut Microbiota and brain function” “Probiotics and prebiotics: use and selection” “Dysbiosis in IBD” “Faecal microbiota transplantation” “Technologies to investigate the human gut microbiota”

GMFH Editing Team
GMFH Editing Team

We have composed short summaries of the workshops that were organized during the Gut Microbiota for Health Summit (Madrid, February 2013).   Here is the list of workshops: “Gut Microbiota and functional bowel disorders” “Gut Microbiota and brain function” “Probiotics and prebiotics: use and selection” “Dysbiosis in IBD” “Faecal microbiota transplantation” “Technologies to investigate the human gut microbiota”

GMFH Editing Team
GMFH Editing Team

Speakers: Dirk Haller (Germany), Balfour Sartor (USA)   Prof. Haller started his presentation by pointing out that “dysbiosis” is not a good term, because nobody knows what dysbiosis really means. To be able to understand what dysbiosis is, you would have to understand what the normal status quo is, and according to Prof. Haller that is not really well established.…

GMFH Editing Team
GMFH Editing Team

Speakers: Dirk Haller (Germany), Balfour Sartor (USA)   Prof. Haller started his presentation by pointing out that “dysbiosis” is not a good term, because nobody knows what dysbiosis really means. To be able to understand what dysbiosis is, you would have to understand what the normal status quo is, and according to Prof. Haller that is not really well established.…

GMFH Editing Team
GMFH Editing Team

Can you tell us about your experience prior to Enterome?   PR: I worked for 14 years as a general practitioner, a family doctor and even as a country doctor. I think it’s worth mentioning because my interest for gut microbiota is based on my experience as a field doctor. This is what I call the “earthly approach to medicine”.…

GMFH Editing Team
GMFH Editing Team

Can you tell us about your experience prior to Enterome?   PR: I worked for 14 years as a general practitioner, a family doctor and even as a country doctor. I think it’s worth mentioning because my interest for gut microbiota is based on my experience as a field doctor. This is what I call the “earthly approach to medicine”.…

GMFH Editing Team
GMFH Editing Team

(27 February 2013) Although considerable progress has been made in determining the impact of the gut microbiota on the development of inflammatory bowel disease (IBD) and other gastrointestinal (GI) diseases, the detailed study and understanding of the composition and effects of this intestinal community still faces numerous methodological and empirical challenges. “Improvement of study design and sample collection, as well…

GMFH Editing Team
GMFH Editing Team

(27 February 2013) Although considerable progress has been made in determining the impact of the gut microbiota on the development of inflammatory bowel disease (IBD) and other gastrointestinal (GI) diseases, the detailed study and understanding of the composition and effects of this intestinal community still faces numerous methodological and empirical challenges. “Improvement of study design and sample collection, as well…

GMFH Editing Team
GMFH Editing Team

Scientists from Brussels University noticed recently in a recent published article that enterotypes could be found also in mice model whatever the genetic background. Although genetic and environmental factor have to be taken in account during any experiment with mice, authors also said that mice enterotypes have also to be controlled. The two first authors of this study, Falk Hildebrand…

GMFH Editing Team
GMFH Editing Team

Scientists from Brussels University noticed recently in a recent published article that enterotypes could be found also in mice model whatever the genetic background. Although genetic and environmental factor have to be taken in account during any experiment with mice, authors also said that mice enterotypes have also to be controlled. The two first authors of this study, Falk Hildebrand…

GMFH Editing Team
GMFH Editing Team